Zoetis (NYSE:ZTS) Stock Purchased by Rep. Gilbert Ray Cisneros, Jr.

Key Points

• Rep. Gilbert Ray Cisneros Jr. purchased between $1,001 and $15,000 of Zoetis stock on September 18, according to a congressional disclosure.
• Zoetis shares opened at $74.32, down 1.8%, while the company reported quarterly EPS of $1.87—slightly above estimates—but revenue declined 0.2% year over year. The company maintained 2026 EPS guidance of $6.15 to $6.25.
• Zoetis declared a quarterly dividend of $0.53 per share, or $2.12 annualized, representing a 2.9% yield. Analysts hold a consensus “Hold” rating with an average price target of $101.08.

Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently bought shares of Zoetis Inc. (NYSE:ZTS). In a filing disclosed on October 12th, the Representative disclosed that they had bought between $1,001 and $15,000 in Zoetis stock on September 18th. The trade occurred in the Representative's "150 MAIN STREET TRUST > BANK OF AMERICA" account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Purchased $15,001 - $50,000 in shares of Benchmark Electronics NYSE: BHE on 10/1/2026.
• Sold $1,001 - $15,000 in shares of Oxford Industries NYSE: OXM on 9/29/2026.
• Sold $1,001 - $15,000 in shares of Semtech NASDAQ: SMTC on 9/29/2026.
• Sold $15,001 - $50,000 in shares of ITT NYSE: ITT on 9/29/2026.
• Sold $1,001 - $15,000 in shares of BridgeBio Pharma NASDAQ: BBIO on 9/29/2026.
• Purchased $1,001 - $15,000 in shares of Tandem Diabetes Care NASDAQ: TNDM on 9/29/2026.
• Purchased $1,001 - $15,000 in shares of Cytokinetics NASDAQ: CYTK on 9/29/2026.
• Purchased $1,001 - $15,000 in shares of Ultragenyx Pharmaceutical NASDAQ: RARE on 9/29/2026.
• Purchased $1,001 - $15,000 in shares of YETI NYSE: YETI on 9/29/2026.
• Sold $1,001 - $15,000 in shares of AtriCure NASDAQ: ATRC on 9/29/2026.

Zoetis Stock Down 1.8%

ZTS stock opened at $74.32 on Wednesday. The stock has a market capitalization of $30.71 billion, a price-to-earnings ratio of 11.50, a price-to-earnings-growth ratio of 1.76 and a beta of 0.74. The company has a 50-day moving average of $73.85 and a two-hundred day moving average of $84.06. Zoetis Inc. has a 52-week low of $68.77 and a 52-week high of $148.30. The company has a debt-to-equity ratio of 2.87, a current ratio of 3.08 and a quick ratio of 1.84.

Zoetis (NYSE:ZTS - Get Free Report) last posted its quarterly earnings data on Thursday, August 6th. The company reported $1.87 EPS for the quarter, topping analysts' consensus estimates of $1.85 by $0.02. Zoetis had a return on equity of 74.89% and a net margin of 27.49%. The business had revenue of $2.47 billion for the quarter, compared to analyst estimates of $2.50 billion. During the same period in the previous year, the company posted $1.76 earnings per share. The firm's revenue for the quarter was down .2% on a year-over-year basis. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. As a group, equities research analysts anticipate that Zoetis Inc. will post 6.20 EPS for the current year.

Zoetis Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 1st. Shareholders of record on Friday, October 30th will be issued a dividend of $0.53 per share. This represents a $2.12 dividend on an annualized basis and a yield of 2.9%. The ex-dividend date is Friday, October 30th. Zoetis's dividend payout ratio is 34.93%.

Hedge Funds Weigh In On Zoetis

A number of hedge funds have recently modified their holdings of ZTS. Moody National Bank Trust Division boosted its stake in Zoetis by 108.5% in the 3rd quarter. Moody National Bank Trust Division now owns 15,927 shares of the company's stock valued at $1,112,000 after buying an additional 8,288 shares in the last quarter. Rockland Trust Co. raised its stake in Zoetis by 19.8% during the third quarter. Rockland Trust Co. now owns 244,065 shares of the company's stock worth $17,043,000 after acquiring an additional 40,294 shares in the last quarter. State Street Corp lifted its holdings in shares of Zoetis by 1.8% during the second quarter. State Street Corp now owns 19,667,723 shares of the company's stock valued at $1,413,323,000 after acquiring an additional 343,322 shares during the period. Tidal Investments LLC lifted its holdings in shares of Zoetis by 22.8% during the second quarter. Tidal Investments LLC now owns 493,507 shares of the company's stock valued at $35,463,000 after acquiring an additional 91,492 shares during the period. Finally, National Pension Service lifted its holdings in shares of Zoetis by 9.6% during the second quarter. National Pension Service now owns 839,875 shares of the company's stock valued at $60,353,000 after acquiring an additional 73,785 shares during the period. 92.80% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

ZTS has been the subject of a number of research analyst reports. TD Cowen cut their price target on Zoetis from $104.00 to $94.00 and set a "buy" rating for the company in a report on Tuesday, August 25th. Weiss Ratings reissued a "sell (d)" rating on shares of Zoetis in a research report on Wednesday, September 9th. Stifel Nicolaus lowered their price objective on shares of Zoetis from $85.00 to $80.00 and set a "hold" rating on the stock in a research note on Thursday, August 20th. Piper Sandler lowered their price objective on shares of Zoetis from $90.00 to $80.00 and set a "neutral" rating on the stock in a research note on Monday, August 10th. Finally, BNP Paribas Exane dropped their target price on shares of Zoetis from $146.00 to $110.00 and set an "outperform" rating on the stock in a research report on Tuesday, August 11th. Eight research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and two have assigned a Sell rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Hold" and a consensus price target of $101.08.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California's 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027. Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California's 31st Congressional District. He declared candidacy for the 2026 election. Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor's degree in political science from George Washington University in 1994, a master's in business administration from Regis University in 2002, and a master's degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

Zoetis Company Profile

Zoetis Inc is a global animal health company that develops, manufactures and commercializes medicines, vaccines, diagnostics and other products for pets and livestock. Its portfolio is designed to help prevent and treat disease, improve animal health and support veterinary care.

The company serves the companion animal market with products for dogs, cats and other pets, including parasiticides, vaccines, dermatology treatments and pain-management therapies. Zoetis also provides animal health products for cattle, swine, poultry, fish and other livestock, along with diagnostic instruments, tests and services used by veterinarians and producers.

Zoetis was established as an independent public company in 2013 after being separated from Pfizer, which had operated the business as Pfizer Animal Health.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.